Pharma Business - January 17, 2023
IRLAB nominates Parkinson’s disease drug candidate
IRLAB Therapeutics has announced that a drug candidate has been nominated from the P003 research project. The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the hallmark symptoms of Parkinson’s without inducing the troublesome complications caused by today’s mainstay anti-Parkinson’s levodopa treatments, states the company. Initiation of development towards clinical studies […]
Biotech Business - January 8, 2023
FDA approves LEQEMBI under the Accelerated Approval pathway
BioArctic’s partner Eisai has announced that under the Accelerated Approval pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) for the treatment of Alzheimer’s disease. The approval concerns lecanemab-irmb (Brand Name in the U.S.: LEQEMBI) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) […]
Agreement - January 5, 2023
Alligator and Orion initiate second immuno-oncology program
Alligator Bioscience has announced an expansion to its research collaboration and license agreement with Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics. The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target […]
Biotech Business - December 21, 2022
Anocca secures 25 million EUR
Swedish Anocca has secured Venture Debt financing from the European Investment Bank (EIB). This significant investment recognizes the strength and high potential of Anocca and its transformational approach to developing T-cell therapies for cancer, the company states. “This financing supports us in moving our first generation of T-cell immunotherapies towards clinical trials in a solid […]
Acquisition - December 12, 2022
SynAct acquires TXP Pharma and carries out a directed share issue
SynAct Pharma has entered into a conditional agreement on acquisition of TXP Pharma, a Swiss-incorporated biotech company researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. The purchase price consists of a fixed purchase price of SEK 136 million and a potential additional purchase price of SEK 55 million, where the […]
Biotech Business - December 8, 2022
Oncopeptides provides update on US marketing authorization
Oncopeptides has announced that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto. The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significant survival result differences for both melflufen and […]
